Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Feb 2 2018

Full Issue

Judge Overseeing 200 Suits Against Painkiller Makers Holds Summit To Get To Root Of Crisis

Taking Purdue Pharma's most powerful pill off the market was one suggestion at the gathering held by U.S. District Judge Dan Polster. Meanwhile, those on the front lines of the epidemic are struggling to deal with the crisis without extra funding from the federal government.

Bloomberg: Purdue’s Oxycontin Targeted At Judge’s Opioid Summit 

Local governments pressing lawsuits to hold pharmaceutical companies responsible for the opioid epidemic told a judge that taking the strongest version of Purdue Pharma Inc.’s Oxycontin painkiller off the market would have immediate results in addressing the crisis, according to people at the meeting. Purdue’s 80-milligram version of Oxycontin is snorted by thousands of abusers, so removing it would be a good first step, experts for cities and counties and state attorneys general told U.S. District Judge Dan Polster, according to three people in attendance at the Wednesday meeting. They spoke on the condition of anonymity because they weren’t authorized to speak publicly about the closed-door summit. (Feeley, 2/2)

Reuters: New York Accuses Insys Of Deceptively Marketing Opioid

Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses. New York Attorney General Eric Schneiderman alleged that the Chandler, Arizona-based drugmaker recklessly marketed its product Subsys for wider uses than the U.S. Food and Drug Administration approved and bribed doctors to prescribe it. (2/1)

Modern Healthcare: Trump's Opioid Priority Still Lacks Congressional Funding 

Every 25 minutes an infant is born to an opioid-addicted mother, and that's when the intense care starts. The average hospital bill to Medicaid in Missouri is about $63,000 per birth of a child with so-called neonatal abstinence syndrome. These babies may experience difficulty eating and breathing, rapid weight loss and sometimes seizures; on average, they stay in the hospital for three weeks after birth. From 2009 to 2012, hospital billing for care of these infants soared from $732 million to $1.5 billion, according to the last comprehensive analysis by Journal of Perinatology. Since that study, addiction rates have only climbed but there has been no more recent estimate of the costs incurred. (Luthi, 2/1)

And in California —

Los Angeles Times: Orange County’s Only Needle Exchange Shuts Down After Santa Ana Denies Permit

Orange County's first and only needle exchange program has shut down after Santa Ana city officials denied its permit application, a move some local advocacy groups and the state's leading public health agency say could negatively affect public welfare. However, the city contends the move was necessary because of an increased number of discarded syringes in the Santa Ana Civic Center, for which it says the needle exchange was at fault. (Brazil, 2/1)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF